NI201500090A - Composiciones de nanopartículas de albúmina y paclitaxel - Google Patents

Composiciones de nanopartículas de albúmina y paclitaxel

Info

Publication number
NI201500090A
NI201500090A NI201500090A NI201500090A NI201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A
Authority
NI
Nicaragua
Prior art keywords
compositions
albumin
paclitaxel nanoparticles
paclitaxel
nanoparticles
Prior art date
Application number
NI201500090A
Other languages
English (en)
Spanish (es)
Inventor
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NI201500090A publication Critical patent/NI201500090A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NI201500090A 2012-12-28 2015-06-26 Composiciones de nanopartículas de albúmina y paclitaxel NI201500090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
NI201500090A true NI201500090A (es) 2015-12-22

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500090A NI201500090A (es) 2012-12-28 2015-06-26 Composiciones de nanopartículas de albúmina y paclitaxel

Country Status (19)

Country Link
US (2) US20140186447A1 (cg-RX-API-DMAC7.html)
EP (1) EP2938340A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016504362A (cg-RX-API-DMAC7.html)
KR (1) KR20150100903A (cg-RX-API-DMAC7.html)
CN (1) CN105007912A (cg-RX-API-DMAC7.html)
AU (1) AU2013370955B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015015319A2 (cg-RX-API-DMAC7.html)
CA (1) CA2896288A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150386A (cg-RX-API-DMAC7.html)
HK (1) HK1216611A1 (cg-RX-API-DMAC7.html)
IL (1) IL239593A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015008361A (cg-RX-API-DMAC7.html)
NI (1) NI201500090A (cg-RX-API-DMAC7.html)
NZ (1) NZ630912A (cg-RX-API-DMAC7.html)
PH (1) PH12015501486B1 (cg-RX-API-DMAC7.html)
RU (1) RU2663687C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201505111TA (cg-RX-API-DMAC7.html)
WO (1) WO2014105644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504762B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
MX388073B (es) 2014-11-25 2025-03-19 Nanobiotix Composición farmacéutica, preparación y usos de la misma.
TW201628644A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
DK3229776T3 (da) 2014-11-25 2023-07-31 Curadigm Sas Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf
HUE056175T2 (hu) 2014-11-25 2022-01-28 Curadigm Sas Gyógyászati készítmények, elõállításuk és alkalmazásaik
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
WO2021086946A1 (en) * 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
EP4375659B1 (en) * 2022-11-28 2025-03-26 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
SG10201609290PA (en) * 2009-08-25 2016-12-29 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
BR112012024349A2 (pt) * 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
MX2015008361A (es) 2016-03-11
RU2663687C2 (ru) 2018-08-08
JP2018087241A (ja) 2018-06-07
JP2016504362A (ja) 2016-02-12
ZA201504762B (en) 2016-10-26
AU2013370955B2 (en) 2018-12-06
US20140186447A1 (en) 2014-07-03
NZ630912A (en) 2017-05-26
CA2896288A1 (en) 2014-07-03
IL239593A0 (en) 2015-08-31
RU2015131141A (ru) 2017-02-03
SG11201505111TA (en) 2015-07-30
CN105007912A (zh) 2015-10-28
PH12015501486B1 (en) 2020-12-16
CR20150386A (es) 2015-10-07
EP2938340A1 (en) 2015-11-04
WO2014105644A1 (en) 2014-07-03
US20190192477A1 (en) 2019-06-27
EP2938340A4 (en) 2016-08-03
KR20150100903A (ko) 2015-09-02
PH12015501486A1 (en) 2015-09-21
AU2013370955A1 (en) 2015-07-16
HK1216611A1 (zh) 2016-11-25
BR112015015319A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
NI201500090A (es) Composiciones de nanopartículas de albúmina y paclitaxel
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CY2018022I2 (el) Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων
PE20151023A1 (es) Triazolopirazinas
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX2022003458A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
CR20150326A (es) Inhibidores de autotaxina
ECSP15026557A (es) Compuestos y sus métodos de empleo
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
GT201500063A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas
CR20120202A (es) Métodos y composiciones para tratar cáncer
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015011753A (es) Metodos para tratar cancer de vegija.
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
ECSP14024526A (es) Derivados bicíclicos de pirazinona
EP2804599A4 (en) PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
UY35055A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
BR112014015753A2 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
UY34776A (es) Formulaciones de bromocriptina
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas